NCT02391545 2023-09-28A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)SecuraBioPhase 1/2 Terminated55 enrolled 13 charts